Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
Arnt V Kristen, Mathew S Maurer, Claudio Rapezzi, Rajiv Mundayat, Ole B Suhr, Thibaud Damy, THAOS investigators, Arnt V Kristen, Mathew S Maurer, Claudio Rapezzi, Rajiv Mundayat, Ole B Suhr, Thibaud Damy, THAOS investigators
Abstract
Aim: Cardiac troponins and natriuretic peptides are established for risk stratification in light-chain amyloidosis. Data on cardiac biomarkers in transthyretin amyloidosis (ATTR) are lacking.
Methods and results: Patients (n = 1617) with any of the following cardiac biomarkers, BNP (n = 1079), NT-proBNP (n = 550), troponin T (n = 274), and troponin I (n = 108), available at baseline in the Transthyretin Amyloidosis Outcomes Survey (THAOS) were analyzed for differences between genotypes and phenotypes and their association with survival. Median level of BNP was 68.0 pg/mL (IQR 30.5-194.9), NT-proBNP 337.9 pg/mL (IQR 73.0-2584.0), troponin T 0.03 μg/L (IQR 0.01-0.05), and troponin I 0.08 μg/L (IQR 0.04-0.13). NT-proBNP and BNP were higher in wild-type than mutant-type ATTR, troponin T and I did not differ, respectively. Non-Val30Met patients had higher BNP, NT-proBNP and troponin T levels than Val30Met patients, but not troponin I. Late-onset Val30Met was associated with higher levels of troponin I and troponin T compared with early-onset. 115 patients died during a median follow-up of 1.2 years. Mortality increased with increasing quartiles (BNP/NT-proBNP Q1 = 1.7%, Q2 = 5.2%, Q3 = 21.7%, Q4 = 71.3%; troponin T/I Q1 = 6.5%, Q2 = 14.5%, Q3 = 33.9%, Q4 = 45.2%). Three-year overall-survival estimates for BNP/NT-proBNP and troponin T/I quartiles differed significantly (p<0.001). Stepwise risk stratification was achieved by combining NT-proBNP/BNP and troponin T/I. From Cox proportional hazards model, age, modified body mass index, mutation (Val30Met vs. Non-Val30Met) and BNP/NT-proBNP (Q1-Q3 pooled vs. Q4) were identified as independent predictors of survival in patients with mutant-type ATTR.
Conclusions: In this ATTR patient cohort, cardiac biomarkers were abnormal in a substantial percentage of patients irrespective of genotype. Along with age, mBMI, and mutation (Val30Met vs. Non-Val30Met), cardiac biomarkers were associated with surrogates of disease severity with BNP/NT-proBNP identified as an independent predictor of survival in ATTR.
Trial registration: ClinicalTrials.gov NCT00628745.
Conflict of interest statement
Competing Interests: A. V. K. has received research support from and served on advisory boards for Pfizer Inc. including the THAOS scientific advisory board. M. S. M. has received support from FoldRx Pharmaceuticals, which was acquired by Pfizer Inc. in October 2010, as a clinical investigator and for scientific meeting expenses. His institution has received grant support from Pfizer Inc. He serves on the THAOS scientific advisory board. C. R. has received unrestricted research grants from Pfizer Inc. He serves on the THAOS scientific advisory board. R. M. is an employee of Pfizer Inc. and holds stock options in Pfizer Inc. O. B. S. served as an advisor for Alnylam Pharmaceuticals, Isis Pharmaceuticals, and Pfizer Inc. as well as having served as an advisor and receiving support as a clinical investigator from FoldRx Pharmaceuticals, which was acquired by Pfizer Inc. in October 2010. He currently serves on the THAOS (natural history disease registry) scientific advisory board. T. D. has received research support from and served on advisory boards for Pfizer Inc. including the THAOS scientific advisory board. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Hammarström P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299: 713–716. 10.1126/science.1079589
- Coelho T, Maurer MS, Suhr OB (2013) THAOS—The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29: 63–76. 10.1185/03007995.2012.754348
- Ando Y, Nakamura M, Araki S (2005) Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 62: 1057–1062. 10.1001/archneur.62.7.1057
- Benson MD (2012) Pathogenesis of transthyretin amyloidosis. Amyloid 19 Suppl 1: 14–15.
- Connors LH, Doros G, Sam F, Badiee A, Seldin DC, Skinner M. (2011) Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid 18 Suppl 1: 157–159.
- Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN (2012) Cardiac transthyretin amyloidosis. Heart 98: 1546–1554. 10.1136/heartjnl-2012-301924
- Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 56: 431–435.
- Saraiva MJ (2002) Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev Mol Med 4: 1–11.
- Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361: 1787–1789. 10.1016/S0140-6736(03)13396-X
- Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120: 1203–1212. 10.1161/CIRCULATIONAHA.108.843334
- Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Röcken C, et al. (2013) Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 164: 179–184. 10.1016/j.ijcard.2011.06.123
- Suhr OB, Ericzon BG (2012) Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 19 Suppl 1: 78–80.
- Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22: 3751–3757. 10.1200/JCO.2004.03.029
- Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, et al. (2010) Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116: 2455–2461. 10.1182/blood-2010-02-267708
- Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107: 2440–2445. 10.1161/01.CIR.0000068314.02595.B2
- Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361: 858–867. 10.1056/NEJMoa0900428
- Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. (2006) Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 48: 2192–2194. 10.1016/j.jacc.2006.06.002
- Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. (2013) The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 29: 77–84. 10.1185/03007995.2012.754349
- Contal C, O’Quigley J. (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30:253–270.
- Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164: 222–228 e221. 10.1016/j.ahj.2012.04.015
- Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. (2003) Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 254: 225–235.
- Jacobson DR, Pan T, Kyle RA, Buxbaum JN (1997) Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Hum Mutat 9: 83–85. 10.1002/(SICI)1098-1004(1997)9:1<83::AID-HUMU19>;2-L
- Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. (2012) Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 93: 1017–1023. 10.1097/TP.0b013e31824b3749
- Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216: 253–261. 10.1002/path.2411
- Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50: 2357–2368. 10.1016/j.jacc.2007.09.021
- Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, et al. (2013) Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 20: 212–220. 10.3109/13506129.2013.825240
- Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, et al. (2008) Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 263: 294–301. 10.1111/j.1365-2796.2007.01888.x
- Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104: 1594–1597.
- Zand Parsa AF, Abdolahi A, Mahdavimazdeh M (2012) Is cardiac biomarkers and left ventricular function affected by chronic kidney disease? Indian Heart J 64: 479–483. 10.1016/j.ihj.2012.08.003
- Westermark P, Bergström J, Solomon A, Murphy C, Sletten K (2003) Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 10 Suppl 1: 48–54.
- Lobato L, Rocha A (2012) Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 7: 1337–1346. 10.2215/CJN.08720811
Source: PubMed